{
    "nctId": "NCT03855423",
    "briefTitle": "Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer",
    "officialTitle": "Malaysian Tocotrienol Rich Fraction: Immunomodulatory Effect in Women With Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer Female",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Physical Assessment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with operable breast cancer\n* Life expectancy of at least 3 months\n* Adequate organ function\n* No allergy to Vitamin E and TRF\n* Provides consent to participate in trial and adhere to the study protocol\n\nExclusion Criteria:\n\n* Receiving concomitant chemotherapy, radiotherapy, hormonal, immune therapy or other investigational drugs\n* Uncontrolled concurrent illness\n* Pregnant / breast feeding women\n* Patients who are unable or unwilling to take Tocotrienols, herbal remedies, or non-prescription medications",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}